Existing users Log In New users Sign up


Free and total prostate specific antigen levels and prostate cancer

DISCOVERIES (ISSN 2359-7232), 2021, October-December issue

CITATION: 

Mediu R, Rama A, Mediu N. Screening for prostate cancer: a study on the free and total prostate specific antigen. Discoveries 2021, 9(4): e139. DOI: 10.15190/d.2021.18


Submitted: July 05, 2021; Revised: Dec. 24, 2021; Accepted: Dec. 24, 2021; Published: Dec. 31, 2021.

 GO BACK to 2021, October-December issue

 GO BACK to DISCOVERIES

Screening for prostate cancer: a study on the free and total prostate specific antigen

Ridvana Mediu (1,*), Ariol Rama (1), Naim Mediu (2)

(1) Faculty of Applied Science, Medical Science Department, University College LOGOS, Tirana, Albania

(2) General surgeon. Surgery Service, Regional Hospital, Durres, Albania


*Corresponding authorsRidvana Mediu, MSC, PhD, Department of Medical Science, Faculty of Applied Sciences, Logos University College, Tirana, Albania; Phone 042405355; Email: ridvana.mediu@kulogos.edu.al 

Abstract

Background: A variety of biomarkers have been developed to monitor growth of cancerous diseases and to detect them at an early stage. Prostate-specific antigen (PSA) is a valuable prostate cancer biomarker that is now widely used for population screening, diagnosis, and monitoring of patients with prostate cancer. Other factors than prostate cancer can cause elevation of PSA levels therefore, free prostate specific antigen measurements in serum have been proposed in order to improve the specificity of laboratory identification of prostate cancer. 

Aim: The aim of our study was to evaluate the diagnostic significance of both total PSA and Free PSA in discriminating prostate cancer from other prostate diseases.

Materials and methods: Our study group consisted of 1201 males admitted at outpatient clinic aged between 35 and 84 years old (mean age 63 years). All laboratory measurements were performed on serum samples. The data were statistically analyzed by using descriptive statistics for Windows. 

Results: The mean total PSA concentration evaluated among 1038 patients was 16.17 ng/mL whereas only Free PSA concentration was evaluated in 163 serum samples and resulted in a mean value of 2.67 ng/ml. In order to calculate the correlation between total and free PSA, data among 69 /1038 patients were further analyzed through statistical program software package for data analysis.

Conclusions: Measuring serum free PSA concentrations along with PSA concentrations may provide higher accuracy for detecting prostate cancer and might eliminate unnecessary biopsies in the men with PSA of more than 4.0 ng/mL. 

Access full text of the manuscript here: 

References

1. Cancer Statistics Review, 1975-2013 - Previous Version - SEER Cancer Statistics Review SEER. [cited 2021 Dec 24]. Available from: https://seer.cancer.gov/archive/csr/1975_2013/index.html

2. Prostate Cancer in Albania [Internet]. World Life Expectancy. [cited 2021 Dec 22]. Available from: https://www.worldlifeexpectancy.com/albania-prostate-cancer

3. Hara M, Koyanagi Y, Inoue T, Fukuyama T. [Some physico-chemical characteristics of “ -seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. Nihon Hoigaku Zasshi Jpn J Leg Med. 1971 Jul;25(4):322–4. 

4. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril. 1973 Feb;24(2):134–44. 

5. Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem. 2000 Jan;46(1):47–54. 

6. Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, et al. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med. 1996 Nov 25;156(21):2462–8. 

7. Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, et al. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J J Assoc Urol Can. 2011 Dec;5(6):416–21. 

8. Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med. 2011 Aug;5(4):515–26. 

9. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer. 1997 Dec 19;74(6):630–6. 

10. Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/Total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. 2003;5. 

11. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995 Sep;154(3):1090–5. 

12. Filella X, Alcover J, Molina R, Rodríguez A, Carretero P, Ballesta AM. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. Eur J Cancer Oxf Engl 1990. 1997 Jul;33(8):1226–9. 

13. Huang JG, Campbell N, Goldenberg SL. PSA and beyond: Biomarkers in prostate cancer. :8. 

14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542–7. 

15. Toren P, Wong L-M, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, et al. Active surveillance in patients with a PSA >10 ng/mL. Can Urol Assoc J J Assoc Urol Can. 2014 Sep;8(9–10):E702–7. 

16. Gandaglia G, Albers P, Abrahamsson P-A, Briganti A, Catto JWF, Chapple CR, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019 Aug;76(2):142–50. 

17. Battikhi MNG. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients. Prostate Cancer Prostatic Dis. 2003 Sep 1;6(3):256–60. 

18. Vashi AR, Oesterling JE. Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin Proc. 1997;72 4:337–44. 

19. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996 Aug;48(2):234–9. 

20. Anderson JR, Strickland D, Corbin D, Byrnes JA, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. Urology. 1995 Jul;46(1):54–7. 

21. Martínez-Piñeiro L, Tabernero A, Contreras T, Madero R, Lozano D, López-Tello J, et al. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total  prostate-specific antigen of 4-10 ng/ml. Eur Urol. 2000 Mar;37(3):289–96. 

22. Gion M, Mione R, Barioli P, Barichello M, Zattoni F, Prayer-Galetti T, et al. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem. 1998 Dec;44(12):2462–70. 

23. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992 Mar;147(3 Pt 2):817–21. 

24. Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol Off J Braz Soc Urol. 2009 Oct;35(5):521–9; discussion 530-532. 

25. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1998 Jan;159(1):5–12. 

26. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004 Jun;50(6):1017–25. 

27. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014 Apr;6(2):74–7.

News & Events Latest news from Discoveries

  • 2022, April| AWARDS!

    2022 Discoveries Award winning articles!

    - Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126. 
    27 citations in the past 1 year - $1000 prize

    - Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108. 
    23 citations in the past 2 years - $400 prize

    Congratulations! Prizes will be received by the awardees on June 1, 2022!.

  • 2021, July| 2021, Jul-September

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| AWARDS!

    2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.